Definitive surgical outcomes in children with advanced hepatoblastoma (PRETEXT III–IV): A retrospective single-center canadian experience
Children with advanced hepatoblastoma (PRETEXT III–IV) often require complex surgical decision-making; however, contemporary data describing long-term outcomes and recurrence patterns across the full spectrum of definitive surgery remain limited. We included 68 patients with PRETEXT III and IV who underwent definitive liver resection (LR, n=41) or liver transplantation (LT, n=27). The primary objective of this study was to characterize survival and recurrence patterns after surgical clearance of primary liver disease. The median age at diagnosis was 18 months (IQR, 9-36). All the patients received neoadjuvant chemotherapy. With a median follow-up of 62 months (IQR, 25–146), 5-year overall survival was 79% (95% CI: 65% - 97%) after LT and 88% (95% CI 78%–100%) after LR. After LT, recurrence occurred in 6 of the 27 (22%) patients, including isolated lung metastases (n=4), combined lung–graft involvement (n=1), and isolated graft relapse (n=1). Recurrence occurred in 6 of the 41 patients (15%) after LR, involving the liver (n=2), lung (n=2), combined liver and pulmonary disease progression (n=1) and unspecified site (n=1). Among LR patients with residual pulmonary nodules at surgery (n=8), progression occurred in three, two of whom died. The majority of events occurred within the first postoperative year after LR or LT. All deaths (n=10, 15%) were attributable to tumor recurrence or progression of known lung metastasis, including all post-LT recurrences. There were no perioperative or graft-related deaths. Univariate analysis showed that a serum alpha-fetoprotein decline of less than 95% and distant metastasis at diagnosis were associated with poor prognosis after LT and LR. Mortality in this cohort was entirely disease-related, occurring after recurrence or progression of residual metastases rather than from surgical modality. Incorporating AFP trend, pulmonary response, and detailed imaging into preoperative assessment may help identify high-risk patients and support more informed surgical decision-making.
Authors
- Yaron Avitzur (ORCID: https://orcid.org/0000-0002-8072-5727)
- Fernanda Takamatsu (ORCID: https://orcid.org/0000-0002-4302-0621)
- Blayne Amir Sayed (ORCID: https://orcid.org/0000-0003-3224-8871)
- Robert Bandsma (ORCID: https://orcid.org/0000-0001-6358-4750)
- Justin Ted Gerstle
- Eveline Lapidus‐Krol (ORCID: https://orcid.org/0000-0001-8798-0723)
- Nicolás Goldaracena (ORCID: https://orcid.org/0000-0002-6623-5561)
- Jennifer Stunguris
- Vicky L. Ng (ORCID: https://orcid.org/0000-0002-9998-5692)
- Binita Maya Kamath (ORCID: https://orcid.org/0000-0002-9982-5023)
- Krista Van Roestel
- Mark S. Cattral (ORCID: https://orcid.org/0000-0001-8416-9660)
- Or Steg Saban (ORCID: https://orcid.org/0000-0001-7281-3949)
- Nicola L. Jones (ORCID: https://orcid.org/0000-0001-5495-0739)
- Furqan Shaikh (ORCID: https://orcid.org/0000-0001-7069-0359)
- Anand Ghanekar (ORCID: https://orcid.org/0000-0003-2966-4145)
- Maria De Angelis
- Julia Hensley
- Sagar Mehta
Institutions
- University Health Network (CA)
- Memorial Sloan Kettering Cancer Center (US)
- Children's Hospital of Philadelphia (US)
- University of Toronto (CA)
- Hospital for Sick Children (CA)
- University of Manitoba (CA)
Publication Details
- Journal
- Liver Transplantation
- Published
- 2026-09-29
- DOI
- https://doi.org/10.1097/lvt.0000000000001006
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00